U.S. Stock Futures Surge as Trump Postpones Iran Strikes, Ceasefire Hopes Rise 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Sterling Slides as Dollar Holds Firm Amid U.S.-Iran Tensions 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBI Holds Interest Rates Steady Amid Middle East Tensions and Global Uncertainty 
Asian Markets Hold Steady Ahead of Trump's Iran Deadline as Oil Tops $110 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Asian Stocks Surge as U.S.-Iran Ceasefire Deal and Samsung Earnings Boost Market Confidence 
European Stocks Hold Steady as Iran Ceasefire Deadline Looms 
Energy Prices and Dollar Climb as U.S.-Iran Conflict Grips Global Markets 
Italy's Service Sector Contracts for First Time in 16 Months Amid Rising Costs and Weakening Demand 
Xi Jinping Pushes Demand-Driven Strategy to Modernize China's Service Sector 
Gold Prices Surge to Three-Week High as Trump-Iran Ceasefire Weakens Dollar 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
RBNZ Holds Rates at 2.25% as Middle East Conflict Fuels Inflation Concerns 
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
